Further investigation is now required to validate the potential safety and efficacy of the partial depletion of SRSF1 in the brain and spinal cords of pre-clinical mammalian models of C9ORF72-ALS/FTD. This evidence concerns the gene SRSF1 and amyotrophic lateral sclerosis.